GeneReach Biotechnology Corp. (4171) AI Stock Analysis

GeneReach Biotechnology Corp.

(TPEx:4171)

Select Model

Rating:40Underperform

Price Target:TWD 14.50▼(-6.15% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by persistent unprofitability and weak cash flow, despite improving revenue, gross margin, and moderate leverage. Technical weakness and a negative P/E further limit the outlook, although oversold momentum indicators provide a modest offset.

Positive Factors

Gross Margin RecoveryThe sharp gross-margin recovery indicates materially better product economics, pricing, mix, or cost performance. If sustained, this improvement can provide a stronger foundation for covering operating expenses and moving the business toward breakeven over the next several quarters.

Negative Factors

Persistent Operating LossesThe shift from healthy profits in 2020–2022 to sustained operating and net losses shows that improved gross profitability has not yet translated into a viable earnings model. Continued losses could constrain reinvestment and increase pressure to stabilize costs and revenue.

GeneReach Biotechnology Corp. (4171) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 872.76M
Dividend Yield: ―
Average Volume (3M): 155.88K
Price to Earnings (P/E): -39.6
Beta (1Y): 0.70
Revenue Growth: 11.99%
EPS Growth: 84.94%
Country: TW
Employees: 120
Sector: General
Sector Strength: 55
Industry: Biotechnology

GeneReach Biotechnology Corp. Business Overview & Revenue Model

Company Description

GeneReach Biotechnology Corp., a company based in Taichung, Taiwan, specializes in the development, production, and commercialization of advanced nucleic acid detection technologies. The company's extensive product line features essential laboratory...

GeneReach Biotechnology Corp. Financial Statement Overview

Summary

Revenue and gross margin improved, while leverage remained moderate and debt declined. However, persistent large losses, negative operating cash flow, declining free cash flow, and shrinking assets and equity materially weaken the financial profile.

Income Statement

28Negative

Balance Sheet

63Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	238.08M	232.74M	206.49M	225.46M	750.02M	1.01B
Gross Profit	173.30M	160.93M	118.28M	27.58M	490.07M	746.98M
EBITDA	14.61M	-8.77M	-36.31M	-143.69M	343.02M	540.70M
Net Income	-43.58M	-110.28M	-118.73M	-166.27M	221.34M	376.62M
Balance Sheet
Total Assets	858.12M	881.05M	1.07B	1.18B	1.62B	1.68B
Cash, Cash Equivalents and Short-Term Investments	395.82M	404.76M	503.76M	531.87M	763.97M	677.27M
Total Debt	220.26M	225.22M	273.01M	257.04M	402.50M	394.61M
Total Liabilities	276.64M	284.34M	341.00M	313.71M	519.23M	596.35M
Stockholders Equity	572.70M	586.73M	716.98M	832.06M	1.07B	1.05B
Cash Flow
Free Cash Flow	190.00K	-20.22M	-31.69M	-60.59M	307.17M	333.20M
Operating Cash Flow	12.05M	-13.86M	-23.22M	-38.67M	357.63M	348.99M
Investing Cash Flow	24.13M	127.00M	-70.21M	-249.91M	-48.01M	-41.70M
Financing Cash Flow	-53.37M	-63.17M	3.43M	-215.88M	-228.28M	43.48M

GeneReach Biotechnology Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4171 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4160	49Neutral	TWD 1.00B	52.78	―	4.93%	0.10%	-44.49%
TW:4171	40Underperform	TWD 896.99M	-39.58	―	―	11.99%	84.94%

* General Sector Average

Performance Comparison

TW:4171 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4171	GeneReach Biotechnology Corp.	15.45	-6.75	-30.41%
TW:4160	Genetics Generation Advancement Corp.	35.70	-15.27	-29.96%
TW:6810	Bio Preventive Medicine Corp.	21.95	-2.75	-11.13%
TW:6850	Bioptic Inc.	27.80	-14.07	-33.61%
TW:6879	Tci Gene Inc.	35.50	-3.65	-9.32%
TW:7725	LabTurbo Biotech Corporation	21.00	-3.30	-13.57%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

GeneReach Biotechnology Corp. AI Stock Analysis